You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (GenomeWeb) – Reproductive health molecular diagnostics firm Inex Innovations Exchange of Singapore is betting on fetal cell-based noninvasive prenatal testing to expand its business in the future.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care.
As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.